Treatment planning for molecular targeted radionuclide therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 3, 2002, Pages 267-280

  Hartmann Siantar, Christine L ^a   Vetter, Kai ^a   DeNardo, Gerald L ^b   DeNardo, Sally J ^b  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Dosimetry; Radiation detection; Radionuclide; Radiotherapy; Therapy

Indexed keywords

MONOCLONAL ANTIBODY I 131; MYELOABLATIVE AGENT; RADIOISOTOPE;

CANCER CONTROL; CANCER RADIOTHERAPY; DOSE RESPONSE; HUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DETECTION; RADIATION DOSE; RADIATION RESPONSE; REVIEW; TREATMENT PLANNING;

ANTIGENS, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 0036062803     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/10849780260179233     Document Type: Review

References (65)

1. A new era for radiolabeled antibodies in cancer?
2. Erfolge der karzinombehandlung an der Dermatologischen Klinik Zurich. Einzeitige hochstosis and fraktionierte behandlung
3. Studien uber diekumulative wirkung der roentgenstrahlen bie frakionierung
4. Dose, time, volume relationships in squamous cell carcinoma of the supraglottic larynx
5. Clinical dose-response curve of human malignant epithelial tumors
6. Analysis of the results of irradiation in the treatment of squamous cell carcinomas of the pharyngeal walls
7. Tolerance of normal tissue to therapeutic radiation
8. Dosimetric precision requirements in radiation therapy
9. Radioimmunotherapy: Choosing an optimal dose for clinical response
10. Dose response relationships in radiation therapy. Application of the logistic regression model
11. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture
12. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours
13. Fitting of normal tissue tolerance data to an analytic function
14. The interplay of radiocurability and tolerance in the irradiation of human cancers
15. The biology of dose-limiting tissues
16. 131I (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
17. Are radiometal-labeled antibodies better than 131I-labeled antibodies: Comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hogkin's lymphoma
18. Yttrium-90/indium-111-DOTA-peptide-chimeric l6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
19. 90Y
20. Microdosimetry and radiocurability: Modeling targeted therapy with β-emitters
21. Prediction of radiation doses from therapy using tracer studies with Iodine-131 labeled antibodies
22. 2 anti-carcinoembryonic antigen monoclonal antibody and autologous hematopoietic stem cell rescue
23. Tumor-targeted radionuclide therapy: Trial design driven by patient dosimetry
24. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji)
25. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3)
26. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody
27. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-1abeled LL2 monoclonal antibody
28. Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies
29. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies
30. Hematologic side effects of radiolabeled immunoglobulin therapy
31. Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy
32. Requirements for a treatment planning system for radioimmunotherapy
33. Treatment planning for internal radiation therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides
34. Monte Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system
35. Estimation of absorbed doses in radioimmunotherapy
36. MABDOS: A generalized program for internal radionuclide dosimetry
37. Treatment planning for radioimmunotherapy
38. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments
39. Radioimmunotherapy dosimetry - A review
40. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
41. A new fiducial alignment system to overlay abdominal computed tomography or magnetic resonance anatomical image with radiolabeled antibody single-photon emission computed tomographic scans
42. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma
43. Description and dosimetric verification of the PEREGRINE Monte Carlo dose calculation system for photon beams incident on a water phantom
44. The MIRD perspective 1999
45. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
46. DOSCAL: A tumor-incorporating mean absorbed dose calculation program
47. Three-dimensional dosimetry for radioimmunotherapy treatment planning
48. Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody
49. Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy
50. Validation of a dose-point kernel convolution technique for internal dosimetry
51. On the possibility of 'real-time' Monte Carlo calculations for the estimation of absorbed dose in radioimmunotherapy
52. A Monte Carlo approach to patient-specific dosimetry
53. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy
54. Internal dosimetry in the use of radiopharmaceuticals in therapy - Science at a crossroads?
55. Dose-volume histogram representation of patient dose distribution in three-dimensional internal dosimetry
56. Pinhole SPECT of mice using the LumaGEM gamma camera
57. The application of pinhole and coded aperture imaging in the nuclear environment
58. Ultra-high resolution brain SPECT imaging: Simulation results
59. Three-dimensional position sensitivity in two-dimensionally segmented HP-Ge detectors
60. 113mIn
61. Hybrid collimation for industrial gamma-ray imaging: Combining spatially coded and Compton aperture data